The Epidermal Growth Factor Receptor (EGFR) Inhibitors Market is being driven by Rise in the prevalence of major cancer indications
The Epidermal Growth Factor Receptor (EGFR) Inhibitors Market is expected to grow at a CAGR of 10.5% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 10732.5 million. The EGFR inhibitor market has experienced significant growth due to the approvals of effective cancer treatments, such as IRESSA, TAGRISSO, ERBITUX, TARCEVA, and TYKERB. These drugs exhibit strong efficacy in treating various cancer indications and inhibiting the uncontrolled division of the EGFR gene. The proven success of EGFR inhibitors in cancer therapy has led to increased research and development efforts. Notably, research institutes and pharmaceutical companies are exploring the potential uses of these drugs beyond cancer indications. Early-stage clinical trials are investigating the efficacy of EGFR inhibitors for the treatment of inflammatory diseases and monogenic disorders, expanding their therapeutic applications.
Get more information on Epidermal Growth Factor Receptor (EGFR) Inhibitors Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
Market Scope |
|
Report Coverage |
Details |
Page number |
203 |
Base year |
2024 |
Historic period |
2019-2023 |
Forecast period |
2025-2029 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.5% |
Market growth 2025-2029 |
USD 10732.5 million |
Market structure |
market_structure.ucfirst |
YoY growth 2024-2025(%) |
9.4 |
Key countries |
US, Germany, India, UK, China, Canada, South Korea, France, Japan, and Italy |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The EGFR Inhibitors Market encompasses small-molecule inhibitors like erlotinib, osimertinib, pyrotinib, vandetanib, icotinib, almonertinib, simotinib, and olmutinib, used in cancer therapy for various clinical applications. These inhibitors target specific kinases, with chemical structures and crystal structures elucidating bonding modes and interactions. Synthetic routes and pharmacological uses are essential aspects, while metabolites and excretion involve glutathione, cysteine, plasma protein, and transmembrane proteins. Lung, liver, and collateral cancers are common indications, with mutations in responsible genes leading to novel EGFR subclasses.
The EGFR inhibitors market encompasses the sales revenue of healthcare applications, IT systems, internet-based healthcare tools, telehealth technologies, digital health technologies, and IT consulting services to healthcare providers and businesses. According to Technavio, the global healthcare market size is determined by the consolidated revenue of equipment, supplies, pharmaceuticals, biotechnology, healthcare technology players, and life sciences tools and services manufacturers and providers. The expansion of the healthcare technology market is influenced by factors affecting both the healthcare industry and IT spending market. Notable drivers include the persistent demand to decrease costs in healthcare sectors across developed and emerging economies. Additionally, the identification and targeting of EGFR mutations in cancer therapy through small molecule inhibitors and their pharmacological uses against specific kinases are significant clinical applications for EGFR inhibitors.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted